Swissmedic launched own GMDP Database
Recommendation
11/12 February 2025
Heidelberg, Germany
Medicinal Products/Drugs meet Medical Devices
The Swiss health authority Swissmedic launched the SwissGMDP Database, similar to the European Medicine Agency's (EMA) EudraGMDP database. It lists the GMP and GDP certificates of all companies in Switzerland with a valid establishment licence issued by Swissmedic. The certificates in the SwissGMDP database include all authorised activities, i.e. unlike EudraGMDP, the GDP activities and Switzerland-specific GMP activities of Swiss companies will also be listed in the certificates. All companies, authorities and individuals can easily view a company's GMP/GDP status using the SwissGMDP database.
Furthermore, SwissGMDP enables a query of all establishment licence holders with a valid establishment license including their sites and licenced operations and will replace the previous table of establishment licence holders.
The SwissGMDP database offers:
- Public access for all users;
- Free-of-charge access to electronic GMP/GDP certificates;
- Access to GDP certificates of companies whose licence covers only GDP activities;
- Inclusion of Switzerland-specific activities;
- Creation of Excel lists based on specific search criteria or for all sites;
- Improvement of the exchange of information between regulatory authorities, industry and the public;
- Support in protecting the medicinal product and active substance distribution chain by making it easier to check legitimate players.
You can find further information on using the SwissGMDP database in the Guidance document.
Related GMP News
04.12.2024Discarded Batch Documentation again found during Inspection
30.10.2024From missing Analysis to Brand Protection Violations - FDA Warning Letter to Canadian Manufacturer
23.10.2024Root Cause Analysis: What can be found in FDA Warning Letters?
23.10.2024Do you want to host FDA Staff? FDA announces Experiential Learning Site Visit Program
09.10.2024Management circumvents Quality Department in Deviation Classification - FDA Warning Letter
09.10.2024Despite MRA: Why does the FDA inspect so frequently in the EU?